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Abstract 
Although improving, the mortality from septic shock still remains high despite increased international awareness. 
As a consequence, much effort has focused on alternative treatment strategies in an effort to improve outcomes. 
The application of blood purification therapies to improve immune homeostasis has been suggested as one such 
method, but these approaches, such as high‑volume continuous haemofiltration or cytokine and/or endotoxin 
removal, have enjoyed little success to date. More recently, the use of sorbent technologies has attracted much 
attention. These adsorbers are highly effective at removing inflammatory mediators, in particular, cytokines, from the 
bloodstream. This narrative review is the executive summary of meetings held throughout the 6th International Fluid 
Academy Days in Antwerp, Belgium (Nov 23–25, 2017), focusing on the current understanding regarding the use of 
such adsorbers in humans with septic shock. We followed a modified Delphi approach involving a combination of 
evidence appraisal together with expert opinion in order to achieve recommendations for practice and, importantly, 
future research.
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Introduction
The pathogenesis of sepsis: blood as “biopsy” of tissue 
inflammation
Septic shock continues to have significant mortality [1]. 
The underlying pathophysiology is complex with both 
pathogenic and host factors (PAMPs (pathogen-associ-
ated molecular patterns) and DAMPs (damage-associ-
ated molecular patterns)) playing a significant role in the 
development and subsequent outcome [2]. However, the 
heterogeneity of septic shock prevents adequate charac-
terization of patients and may hinder subsequent clinical 
intervention(s). Sepsis and septic shock affect anywhere 
between 100 to 1000 per 100,000 person-years and 19 
per 100,000 person-years depending on the cohort stud-
ied [3–6], with reported mortality rates ranging between 
20 to 50% [7–11]. Moreover, the reported incidence is 
increasing, although this may be attributed to reporting 
bias in so-called claims-based databases, as data analysis 
on electronic health records cannot confirm this trend 
[12–15]. Therefore, it is of no surprise that the treatment 
of sepsis has become a major global health issue. Indeed, 
in the USA during 2011 sepsis accounted for just over 5% 
of total hospital costs corresponding to $20 billion dollars 
[16].
The place for blood purification
Patients with sepsis are often treated in areas of intensive 
care given that close monitoring and intense therapeutic 
support are needed [17]. Early treatment includes the use 
of timely, appropriate antibiotics, intravenous fluids, oxy-
gen therapy as well as vasopressor and inotropic support 
where needed. Other additional treatments including 
extracorporeal or so-called blood purification techniques 
(BPT) have also been tried [18]. These techniques include 
(among others): haemofiltration, haemoperfusion, inter-
mittent or continuous high-volume haemofiltration 
(HVHF), plasmapheresis or adsorption. The rationale 
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behind such an approach is to achieve “immune homeo-
stasis” which theoretically reduces the potential damage 
caused by dysregulation of the host response to infection. 
This may be heralded by a profound rise in inflamma-
tory mediators including cytokines which contribute to 
the dramatic systemic effects of sepsis, mainly in septic 
shock [9, 19]. The recently updated Sepsis 3.0 consensus 
definitions state that sepsis is an infection accompanied 
by life-threatening organ dysfunction caused by a dys-
regulated host response [20]. Given the pivotal role of 
cytokine production in sepsis, it follows that removal of 
these substances, through such BPT, may attenuate the 
response particularly in the early phase of sepsis [21]. 
Several hypotheses have been proposed as to the poten-
tial mechanisms underpinning potential benefit. These 
include cytotoxic theories including the peak concen-
tration hypothesis whereby all inflammatory mediators 
are removed at a given rate, dependent on the BPT used 
and assuming they are filtered [21–24]. Alternatively, the 
cytokinetic theory proposes that cytokines are removed, 
thereby creating a cytokine gradient between the blood-
stream and tissues allowing leucocyte-enhanced traffick-
ing [25]. In the same line, cytokine levels can also be seen 
as communicating messengers to talk to cells, recruit 
some, depress others and reduce cell metabolism for 
others [22]. Despite early promise, no multicentre rand-
omized controlled studies have demonstrated a survival 
benefit including the use of HVHF where higher flows 
may lead to increased cytokine removal were tried (the 
cytotoxic threshold immune modulation hypothesis) 
[26–28]. Other extracorporeal blood purification thera-
pies also have failed with significant outcome data lacking 
with no treatment demonstrating a translatable survival 
benefit in any randomized controlled study [29–31]. This 
somewhat too simplistic view takes into account several 
new concepts. Indeed, blood level of mediators (more 
than cytokines) implies the saturation of the interstitial 
and cellular compartments to be present in the blood. 
It is the so-called tip of the iceberg theory [31]. This 
theory is very similar to the “threshold immune modu-
lation theory” [23]. In addition, plasma mediator levels 
depend on several factors: the intensity of production, 
the number of cell receptors availability, the clearance 
of such mediators, the affinity of the receptors for such 
mediators. As an example, the interleukin (IL)-6 receptor 
is an agonist one, which differs from tumour necrosis fac-
tor (TNF)-soluble receptors and IL-1 receptors that are 
inhibitory; the consequence is that a low IL-6 level with 
a high level of receptor induces more cellular response 
than high level of IL-6 with a low level of receptors [22]. 
This very important issue is showing that an IL-6 level 
alone may not be very predictive of the future response 
of the organism. DAMPs are also playing a key role and 
especially the endosomal DAMPs that are eliminated 
via the BPT and are capable of inducing cellular damage 
and apoptosis [32]. This may explain the initial “positive” 
observational trials with HVHF. The reported improve-
ment in hemodynamic status associated with or not with 
lactate reduction might mainly be the result of the fluid 
replacement therapy made with large volumes of crystal-
loids containing high buffer concentrations. As a conse-
quence, the induced pH increase might have changed the 
affinity for catecholamines to their receptors improving 
hypotension [28–30].
Impact on mortality
Extracorporeal haemoperfusion with Polymyxin B (PMX-
HP) has shown improvement in organ dysfunction and 
a survival benefit in small studies [33] including a small 
randomized trial [34], while larger trials failed to confirm 
these findings [35, 36]. Evaluating the use of PMX-HP in a 
randomized controlled trial of adults treated for endotox-
emia and septic shock (the EUPHRATES study) included 
patients with persistent septic shock despite adequate 
fluid resuscitation and vasopressor treatment [37]. An 
endotoxin activity assay (EAA) was applied. No mortality 
difference was observed in the “per protocol population” 
(n =  244, multiple organ dysfunction score (MODS) > 9, 
EAA ≥ 0.6). However, among the patients in refractory 
shock with MODS of more than 9 and an EAA between 
0.6 and 0.9, a significant 10.7% reduction in 28-day mor-
tality in a post hoc analysis was recognized after receiv-
ing two sessions of PMX-B-HP [38]. Post-hoc analysis 
revealed a significant mortality reduction when the EAA 
was limited to less than 0.9, which may suggest an upper 
limit to a pre-treatment endotoxin burden under these 
treatment conditions [38]. A recent meta-analysis of 
17 trials demonstrated that PMX-B-HP treatment may 
reduce mortality in patients with severe sepsis and sep-
tic shock. The included studies were stratified into three 
groups based on the mortality rates of the conventional 
treatment group: low-risk group (mortality rate < 0.3), 
intermediate-risk group (0.3–0.6) and high-risk group 
(> 0.6). Risk ratios with 95% confidence intervals (CI) for 
the mortality-stratified analysis between the PMX-HP 
and conventional treatment groups were calculated and 
presented as summary statistics. This a posteriori classifi-
cation can be seen as a major caveat of this meta-analysis. 
Also mortality rate does not reflect cytokine concentra-
tions and load and therefore is not a predictor of response 
to cytokine removal. Disease severity subgroup meta-
analysis revealed a significant risk reduction in overall 
mortality in the intermediate-risk (mortality rate 0.3–0.6) 
and high-risk (mortality rate > 0.6) groups, but not in the 
low-risk (mortality rate < 0.3) group reinforcing the view 
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that rigorous patient selection is crucial for treatment 
success [39].
Lastly, two editorials set the pace by stating that while 
blood purification in sepsis remains a valid approach, the 
use of adsorbers and their current efficacy of endotoxin/
cytokine elimination cannot be recommended to reduce 
the mortality in absence of positive randomized con-
trolled trials (RCTs) [40, 41].
Cytokine storm and capillary leak
Capillary leak represents the maladaptive and undesir-
able movement of fluid and electrolytes with or without 
protein into the interstitium that generates anasarca and 
end-organ oedema potentiating organ dysfunction and or 
failure [42]. The global increased permeability syndrome 
(GIPS) defined as a positive cumulative fluid balance 
and new onset organ dysfunction/failure is described in 
patients with persistent systemic inflammation resulting 
in continuing transcapillary albumin leakage. GIPS may 
represent the third phase in a continuum after the initial 
cytokine storm and ischaemia–reperfusion injury and 
could be a potential indication to start BPT [43].
Finding the answers
The focus of this consensus meeting was to determine 
whether a reduction in cytokine levels is possible through 
the use of sorbent technology by use of the  CytoSorb® 
(Cytosorbents, Corporation, New Jersey, USA) device. 
This consists of a single-use haemoadsorption cartridge 
which can be used with standard blood pumps, such as 
those found on RRT machines or through a haemoperfu-
sion device [44–46]. The CytoSorb cartridge is the only 
currently available CE-marked device shown to consist-
ently lower excessive cytokines in severe sepsis. The car-
tridge is filled with sorbent beads made from a porous 
polymer that adsorbs and capture cytokines as blood 
passes through the device. This process is concentra-
tion dependent, and so the higher the levels of cytokines 
in the blood, the faster the levels are reduced. Although 
CytoSorb therapy has been described for other indica-
tions, including intoxications, rhabdomyolysis, hyper-
bilirubinemia, etc., we chose to concentrate on human 
studies in sepsis and septic shock.
Consensus process
This consensus meeting took place during the 6th Inter-
national Fluid Academy Day (IFAD) held in Antwerp, 
Belgium, at the end of November (November 23–26, 
2017). We followed a modified Delphi approach involv-
ing a combination of evidence appraisal together with 
expert opinion in order to achieve recommendations 
for practice and future research. A panel of clinicians 
representing intensive care, anaesthesia and critical 
care nephrology from Europe convened to discuss the 
issues related to cytokine haemoadsorption using the 
 CytoSorb® or other devices in humans with sepsis and 
septic shock. The participants were tasked with sum-
marizing the literature in humans to date, highlighting 
knowledge gaps and recommending areas of potential 
research. Reviews of the literature were performed prior 
to the meeting with a presentation to the participants 
and consensus was reached.  MEDLINE® and PubMed 
searches were performed using the search terms “cyto-
sorb”, “haemofiltration”, “haemoadsorption”, “haemoper-
fusion” and “‘sepsis OR septic shock OR critical care OR 
critical illness’”. The reference lists of identified papers 
were screened to identify other relevant papers. Where 
necessary, further discussion was performed after the 
meeting. Although representatives from industry were 
present, they did not contribute to the discussion unless 
specifically questioned and did not play a role in the 
manuscript preparation. This paper serves as the final 
Executive Summary of the meeting.
Pathophysiology
As discussed, the inflammatory state associated with 
sepsis leads to release into the circulation of many pro-
inflammatory mediators leading to deleterious systemic 
effects [44]. Although this effect may in part be modi-
fied through anti-inflammatory mediators, sustained 
effects may lead to relative immunoparesis [47, 48]. This 
concept is important given the overused simplistic view 
that sepsis is associated with a significant uncontrolled 
release of pro-inflammatory mediators and simple mod-
ulation of these would translate into improved patient 
outcomes [21]. Hence the desire for a more specific tar-
geted therapy, rather than just adoption of “standard” 
continuous renal replacement techniques as a profound 
pro-inflammatory response, may lead to dysregula-
tion of the anti-inflammatory pathways, and the aim of 
immune homeostasis may be thwarted by a worsening 
of the host response (Figs.  1, 2). Indeed, such dysregu-
lation can be seen in patients with sepsis who transi-
tion to a late anti-inflammatory phenotype referred to 
as sepsis-associated immunosuppression (SAI) [49–51]. 
This process involves the reduction in the production of 
the inflammatory mediators together with direct effects 
on antigen-presenting activity. In turn, this may lead 
to enhanced immune tolerance with changes demon-
strated in circulating immune cells and within tissues 
[52]. Following injury or infection, there is activation of 
humoral factors such as complement that then trigger 
the antigen-presenting cells (APCs) that release a host of 
mediators including cytokines. In turn, these attract and, 
as a consequence, activate more APCs and neutrophils. 
Migration to draining lymph nodes stimulates further 
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adaptive immune activity. These processes are followed 
by the anti-inflammatory response whereby there is a 
diminution of the host response as a consequence of 
anti-inflammatory cytokines such as IL-10 being pro-
duced. In the critically ill, this may lead to immunosup-
pression as described [47, 48]. Cytokines play a pivotal 
role in the progression of the sepsis response. In early 
sepsis TNF-α, a pro-inflammatory cytokine released by 
monocytes and macrophages, is a marker of early sepsis 
and enhances the adaptive immune response [53]. Sev-
eral studies have demonstrated an association between 
mortality and elevated TNF-α although the utility of 
TNF-α as a predictor of mortality has been questioned 
[54]. IL-6, predominantly produced by monocytes and 
macrophages, induces T-cell activation and B cell pro-
liferation and stimulates the acute phase response all 
leading to augmentation of the immune response [55]. 
Circulatory levels rise rapidly after infection with peak 
levels approaching 2  h after insult with increased levels 
associated with poorer outcomes. However, cytokines 
may be derived from non-immune cells and have vari-
able clearance rates and as such may not reflect immune 
cell functionality in all cases [56]. Furthermore, IL-6 has 
a relatively fast induction coupled with a short half-life, 
and these characteristics make it ideally suited for patient 
monitoring although to date most laboratories do not 
offer routine assay. With regard to anti-inflammatory 
cytokines, IL-10 is the most studied and has similar kinet-
ics to IL-6. However, unlike IL-6, Il-10 induces antigen 
tolerance enhancing SAI and may predict mortality [57]. 
Obviously, considering IL-6 as a potential target remains 
interesting, but the profile of IL-6 kinetics in critically ill 
patients could be heterogeneous and explained by several 
factors. Indeed, in the abdomix study, some patients were 




The enhanced inflammatory response seen in septic 
shock is associated with a high mortality [57, 58] corre-
lated with the production of pro- and anti-inflammatory 
mediators [57] rather than disequilibrium between pro- 
and anti-inflammatory mediators [59] (Fig.  3). This has 
stimulated much effort towards potential attenuation of 
this response particularly as early studies suggested that 
continuous veno-venous haemofiltration (CVVH) may 
reduce cytokine levels [60]. However, as discussed, these 
Fig. 1 Cytokine response after sepsis. Normal and abnormal immune response after an (infectious) insult (A). Recovery with regaining of the 
homeostatic balance occurs when pro‑inflammatory (solid red line) and anti‑inflammatory (solid blue line) mediators (B) return back to baseline 
levels. Early death or fulminant septic shock (C) can occur following early increased innate pro‑inflammatory response (cytokine storm, dotted 
red line) or after initial adaptive immunosuppression (dashed blue line). Immunoparalysis (D) can occur following early increased adaptive 
anti‑inflammatory response (immunosuppression, dotted blue line) or after initial pro‑inflammatory response (dashed red line). Haemoadsorption 
with  Cytosorb® may attenuate the initial pro‑ (bold red line) and anti‑inflammatory (bold blue line) response resulting in early recovery (E)
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Fig. 2 Balance between the pro‑ and anti‑inflammatory mediators. a Following an initial (infectious) insult (A), normally after correct (antibiotic) 
treatment the antagonistic forces of pro‑inflammation (B), and anti‑inflammation (C) regain balance (grey area shows net effects) maintaining 
healthy homeostasis (D), that will lead to recovery and survival (E). Adapted from Pfortmueller et al. with permission (Open Access CC BY Licence 
4.0) Intensive Care Medicine Experimental (2017) 5:49 https ://doi.org/10.1186/s4063 5‑017‑0163‑0. b Following an (infectious) insult (A), during a 
dysregulated host response the pro‑inflammatory (B) forces initially overwhelm anti‑inflammation (C) resulting in an imbalance (D), followed by 
immunosuppression and increased anti‑inflammatory mediators (grey area shows net effects). With different therapeutic interventions recovery (E) 
can be obtained or delayed (E’) or the patient can evolve into a state of persistent immunosupression or paralysis. Adapted from Pfortmueller et al. 
with permission (Open Access CC BY Licence 4.0) Intensive Care Medicine Experimental (2017) 5:49 https ://doi.org/10.1186/s4063 5‑017‑0163‑0
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early observations have not translated into clinical bene-
fit. Meta-analysis suggests that the only potentially effec-
tive BPT for the treatment of sepsis are plasma exchange 
or haemoadsorption particularly with Polymyxin B [2, 
39]. Although initial results using Polymyxin B haemop-
erfusion showed promise [31], this has not been borne 
out by subsequent randomized clinical trials [32]. Given 
the remit of sorbent technologies, we chose to focus on 
the use of CytoSorb as a haemoadsorption device. The 
adsorber has a surface of about 45,000 m2 compared to a 
conventional hemofilter with a surface of 1–1.5 m2 with a 
molecular cutoff of about 60 kDa removing cytokines as 
well as other toxins and drugs. As a consequence, Cyto-
Sorb does not adsorb endotoxin which has a molecu-
lar weight of 100  kDa. CytoSorb is saturable regarding 
adsorption in the clinical setting (mostly after 8 h) as evi-
denced by an rebound increase in the dose of vasopres-
sors which can be tapered when changing the CytoSorb. 
So far, in vitro studies have not been evaluated regarding 
the adsorption–saturation process of adsorption. This 
could be an interesting area for future research. Multiple 
pre-clinical studies using animal models of sepsis have 
Fig. 3 The rationale of bulk removal of cytokines during cytokine storm. When homeostasis is normal, the pro‑inflammatory (open circles), and 
anti‑inflammatory (closed circles) mediators are in balance, molecules are present evenly as demonstrated in the first panel of the figure (a). When 
molecules are adsorbed in this scenario, the removal rate of both should be similar. However, if one component is in abundance—which is the 
case during cytokine storm (b), then the removal rate should be proportionally higher from the mediator that is present in large numbers. This 
demonstrates the rationale why bulk removal of cytokines during cytokine storm may help to regain homeostatic balance
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demonstrated reductions in various circulating cytokines 
and chemokines, reduced organ injury, and improved 
survival [61–64].
Impact on different cytokines
In a feasibility study, the removal of cytokines was con-
firmed with cytokine extraction rates approaching 30% 
[65]. In this study, plasma concentrations of both IL-6 
and TNF-α, but not IL-10, were significantly reduced 
after the first hour of therapy [65]. Overall removal was 
greatest for IL-6, 28% (p = 0.006), and least for tumour 
necrosis factor, 8.5% (p = 0.13). However, plasma con-
centrations for all three cytokines increased over time 
and were above baseline by the end of the intervention 
(4 h). In a more recent study, the group of Antoine Sch-
neider [66] conducted a single-centre pilot randomized 
controlled trial in 30 patients undergoing elective cardiac 
surgery and deemed at risk of complications. Patients 
were randomly allocated to either standard of care 
(n = 15) or  CytoSorb® haemoadsorption (n = 15) during 
cardiopulmonary bypass (CPB). The primary outcome 
was the difference between the two groups in cytokines 
levels (IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, TNF-
α, interferon gamma (IFN-γ), monocyte chemotactic 
protein-1 (MCP-1) measured at anaesthesia induction, 
at the end of CPB, sand 6 and 24 h post-CPB initiation. 
However, the intervention was associated neither with a 
decrease in pro- or anti-inflammatory cytokine levels nor 
with any improvement in relevant clinical outcomes [66]. 
These results are conflicting, and this is obviously a major 
concern regarding this new technique. So, altogether, no 
study using CytoSorb has shown a sustained plasma con-
centration reduction lasting during the whole treatment. 
Given the possibility that this technique may hold prom-
ise, we reviewed available data with the aim of produc-
ing current consensus statements and directing further 
research [67–69].
Does the use of CytoSorb haemoadsorption 
therapy in patients with sepsis or septic shock 
demonstrate any clinical benefit?
Although there is a significant body of experimental 
evidence supporting the potential use of haemoadsorp-
tion with CytoSorb in septic shock, there is far less evi-
dence from human studies. There are over 100 case 
studies describing the use of CytoSorb in many clinical 
scenarios, and in general, the treatment is well toler-
ated, but clinical studies in general are small case series 
[70–72]. The largest study to date, a randomized con-
trolled, open-label study enrolled patients from 10 Ger-
man study sites over the period 2008–2011 [73, 74]. 
A total of 582 patients were screened for this study of 
which 100 mechanically ventilated patients with severe 
sepsis or septic shock together with acute lung injury or 
acute respiratory distress syndrome were recruited. Final 
analysis was limited to 97. Remarkably, no data regarding 
hemodynamic indices such as cardiac index or systemic 
vascular resistance was recorded. Patients were rand-
omized initially on a 1:1 basis using sealed envelopes, but 
due to suspected irregularities, this system was changed 
after 32 patients were recruited to an electronic system 
using a block length of 6. The treatment arm received 
6 h of CytoSorb haemoperfusion per day for up to 7 days 
compared to standard care. The primary endpoint was a 
reduction in “normalized” rather than absolute IL-6 lev-
els with post-treatment IL-6 levels divided by the individ-
ual patients’ baseline IL-6 concentration. Unfortunately, 
in 22 patients, no valid primary endpoint was available 
leaving 75 patients in the final cohort. Secondary end-
points included a host of other cytokines, duration of 
mechanical ventilation, 28-day mortality and the MOD 
score. The primary endpoint of this study was negative. 
The use of haemoadsorption was not associated with a 
reduction in IL-6 levels. After adjusting for comorbidities 
(age, gender, and RRT), there was no association between 
treatment with haemoadsorption and mortality or indeed 
any of the other secondary endpoints. What was noted 
was that there were a larger number of clinically signifi-
cant patients needing RRT in the treatment group (31.9% 
vs 16.3%). Although the application of the CytoSorb car-
tridge did result in detectable IL-6 elimination (5-18%) 
throughout the 6-h period, this did not translate to an 
overall reduction compared to control. This may appear 
incongruous as the effects of treatment on IL-6 between 
groups were measured at day 2 and not during the time 
periods employed to assess IL-6 removal (15, 60, 180 and 
360 min, respectively) [73, 74].
Although this can be regarded as the first randomized 
controlled trial (RCT) employing the CytoSorb technique 
in sepsis, the results do not provide any evidence that 
treatment resulted in a clinically relevant endpoint. The 
study was powered for safety and efficacy of IL-6 removal. 
The patient population included was also less sick then in 
case series and in a recent registry [75], suggesting that 
since 2008, CytoSorb has been used in a sicker popula-
tion. Similarly, a prospective randomized control trial in 
patients who underwent cardiac surgery also found no 
significant impact on cytokine concentrations although 
this study was not performed in sepsis [76]. In a recent 
propensity-matched retrospective study on 32 patients, 
the influence of intraoperative cytokine adsorption on 
the perioperative vasoplegia, inflammatory response and 
outcome during orthotopic heart transplantation was 
investigated [77]. Intraoperative CytoSorb treatment was 
associated with reduced vasopressor demand and less 
frequent RRT with no difference in length of mechanical 
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ventilation and ICU stay [78]. Other case series in sep-
sis patients do point to a reduction in vasopressor dose, 
which may be considered a relevant endpoint, although 
these are not randomized studies [68–70]. The third 
interim analysis of the CytoSorb Registry [75] of 135 
patients with septic shock and an acute physiology and 
chronic health evaluation II (APACHE-II) predicted 
mortality of 78% had an observed mortality of 65% with 
a marked reduction in both PCT and IL-6 levels after 
24 h [75]. Such an high predicted mortality (78%) can be 
explained by various reasons. First, it was recommended 
to only use Cytosorb haemoadsorption in patients with 
an APACHE-II score above 25. Second, clinicians were 
only starting the treatment as a salvage therapy, late 
in the course of the disease. Obviously, with a registry, 
you cannot control the eligibility criteria. Recently, the 
first randomized clinical trial on CytoSorb as a stand-
alone (i.e.: without CRRT) haemoperfusion treatment in 
patients with septic shock, the ACESS trial (Adsorption 
of Cytokines Early in Septic Shock) was published [78, 
79]. This was a proof of concept pilot study on 20 medi-
cal patients randomized into a CytoSorb and a stand-
ard treatment group, with cytokine adsorption initiated 
within the first 24 h after the onset of septic shock. The 
treatment proved to be safe and resulted in a significant 
reduction in norepinephrine requirement in the Cyto-
Sorb group as compared to controls: T0 = 0.54[IQR: 
0.20–1.22], T48 = 0.16[IQR: 0.07–0.48], p = 0.016; 
Controls: T0 = 0.43[IQR: 0.19–0.64], T48 = 0.25[IQR: 
0.08–0.65] µg/kg/min. They also observed a signifi-
cant reduction in procalcitonin (PCT): CytoSorb: T0 
median = 20.6[IQR: 6.5–144.5], T48 = 5.6[1.9–54.4], 
p = 0.004; Control: T0 = 13.2[7.6–47.8], T48 = 9.2[3.8–
44.2] ng/mL [78, 79]. The promising results of this pilot 
study may serve as the rationale of further large ran-
domized clinical trials, but at present, there is a lack of 
robust evidence to support recommendations.
Results of the consensus meeting
To date, there is not enough data to provide any kind of 
evidence-based recommendations for the use of sorbent 
technologies, but the following points were considered 
by the panel as most important unanswered questions 
which may aid further recommendations.
Point‑1: Which patient would benefit the most 
from cytokine removal?
The aim of any treatment is to select only patients who 
have a high probability of benefit from the intervention. 
To date, most of the case series included patients with 
a high predicted mortality in keeping with septic shock 
although few have included cytokine estimation [64, 
71]. Where recorded, there is significant variation in 
IL-6 levels, and therefore, one may conclude that some 
patients were treated where benefit would be negligible if 
indeed [IL-6] levels are predictive of response to therapy. 
Therefore, any future studies should attempt to enrich 
the study population through cytokine measurement or 
another marker of potential therapeutic response such 
as PCT [70]. A threshold PCT concentration may be 
included as an inclusion factor in future studies. Alter-
natively, patient selection may concentrate on those indi-
viduals who require high doses of vasopressor agents to 
maintain adequate organ perfusion as a reduction in such 
drugs is a meaningful clinical outcome which may trans-
late into other benefits [78, 79].
Point‑2: When to start cytokine removal therapy in sepsis?
The timing of therapy remains an issue in many aspects 
of critical care medicine not least those involving extra-
corporeal therapies. Several of the case series report a 
less favourable outcome in those individuals who com-
menced treatment more than 24  h after diagnosis [70]. 
Data of the ACESS trial also support the concept of 
starting treatment within 24  h [78, 79]. It follows that 
any recommendation regarding timing of therapy will 
be dependent on the patient population and how pro-
spective individuals are selected. Where the primary 
endpoint is a reduction in vasopressor, then timing will 
be relatively easy to define, whereas cytokine levels may 
be less clear especially given the differences in kinetics. 
Certainly, the rationale for any of the blood purification 
therapies would point to commencing treatment early in 
the disease process in order to maximize benefit. Maybe 
starting therapy directly in operating room during sur-
gery for peritonitis patients with already hemodynamic 
impairment and catecholamine requirement should be 
considered for future studies. However, timing to inter-
vene might be even more complex especially when sep-
sis-induced immunodepression is taken in account. This 
depression is essential to limit the consequences on the 
host tissues of the host response related to infection (i.e. 
maintain the inflammation–repair–healing cycle). Char-
acterization of this immunodepression might be one of 
the best indicators to decide when to use adsorber tech-
nique to reduce inflammation, namely when the down-
regulation is modest or absent [22].
Point‑3: How long should cytokine removal therapy last 
and how long should it be continued?
The optimum length of treatment is still undecided. 
Moreover, the length of time of initial therapy is also 
unclear. Schadler et al. treated patients for 6 h a day for 
7  days [73, 74], whereas other reported studies either 
did not describe the treatment period or used the car-
tridge for 24 h [70, 71]. No evidence to date exists for the 
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appropriate duration of adsorption therapy or indeed the 
initial treatment period. Again, this may be directed in 
future studies by the use of IL-6 or rather PCT as a sur-
rogate for total cytokine removal and reduction in sys-
temic levels coupled with clinical improvement may be a 
logical place to start regarding treatment times. Also, it 
is unknown whether the initial therapy should be for 12 
or 24 h. Again, a pragmatic approach may be directed by 
cytokine estimation. Again, the study by Schadler [73, 74] 
may provide some answers. Although the 6-h treatment 
did not result in an overall reduction in IL-6 compared 
to controls over a 24-h period, there was increased IL-6 
elimination with the use of haemoadsorption [73, 74]. It 
follows that if the aim of treatment is to reduce cytokine 
levels, then a prolonged treatment period should be 
associated with a reduction in systemic levels. However, 
this removal in cytokines may be attenuated by cytokine 
shift from the interstitium into the blood compartment 
thereby negating any overall effect [22, 68, 69]. As a con-
sequence, pharmacokinetic studies on cytokine clear-
ance would be extremely useful to conduct in the future 
to better delineate the therapy duration of hemadsorp-
tion in relation to benefits for the patient with a cytokine 
storm.
Point‑4: Which patient population should be studied 
in the future?
Future studies should aim to include as homogeneous 
cohorts of septic shock patients, especially those with 
very high vasopressor needs. Another interesting popu-
lation to study may be patients with acute respiratory 
distress syndrome (ARDS). Mortality rate of ARDS still 
remains high between 30 and 50% [80]. ARDS is a het-
erogeneous syndrome, characterized by increased pul-
monary capillary permeability [81]. It is the accumulation 
of protein-rich fluid inside the alveoli that triggers dam-
age to the capillary endothelium and alveolar epithelium 
leading to release of cytokines, producing diffuse alveo-
lar damage [82]. Extracorporeal membrane oxygenation 
(ECMO) may serve as a salvage therapy with the CESAR 
trial that have led to an enhanced use of this therapy [83]. 
Several case reports mention the positive effect of incor-
poration of CysoSorb therapy for respiratory failure due 
to ARDS, using ECMO and CytoSorb therapy. The use of 
CytoSorb appeared to result in rapid resolution of neu-
tropenia, reversal of toxic shock and rapid weaning of the 
high-dose vasopressor infusions and a significant reduc-
tion in the levels of circulating inflammatory mediators 
[84–88].
Point‑5: What severity of sepsis would be the most 
appropriate to include in a study looking at cytokine 
removal therapy in patients with sepsis?
The intervention is more likely to benefit patients with 
high severity of illness (e.g. APACHE-II greater than 
25) [75]. Refractory shock indicated by high doses of 
vasopressor support and early multiple organ failure 
with some evidence of a cytokine storm (i.e.: high PCT) 
should be preferred [70, 71, 79].
Point‑6: Which biomarker should be the most appropriate 
to include in a study looking at cytokine removal therapy 
in patients with septic shock?
It is uncertain whether cytokine concentrations can iden-
tify the ideal patient for treatment. Detecting persistent 
‘cytokine storm’—despite adequate resuscitation and 
source control—could be an alarming signal that cytokine 
removal may be beneficial. PCT as one of the most stud-
ied inflammatory biomarker in sepsis could be added as a 
biomarker to determine in which patient to start therapy 
[87, 88]. It is difficult to determine the absolute cutoff val-
ues above which treatment may be indicated, but there is 
some evidence, that PCT kinetics, i.e. failure of PCT to 
decline or rapidly increasing levels may help to identify 
persisting cytokine storm [89]. It is indeed the reality that 
the molecular weight of PCT is about 13 kDa and PCT 
might be removed by the adsorbent. Therefore, PCT is a 
good biomarker to decide when to start but not to follow 
the response to therapy nor to decide when to stop. IL-6 
may also be a promising biomarker, but at present, little 
is known about IL-6 kinetics, and its response to appro-
priate or inappropriate treatment, which needs further 
research. Nevertheless, the biomarkers to characterize 
inflammatory status cannot be summarized by limited to 
IL-6 associated and PCT: we also do need to obtain infor-
mation on cellular function (immune and tissular) [22].
Point‑7: Future research recommendations
Based on the above, future studies must define the popu-
lation in terms of physiological parameters (APACHE-II) 
or SOFA (Sequential Organ Failure Assessment) scores 
[90], vasopressor requirement, etc.), and there should 
be biomarker enrichment of patient selection probably 
using markers such as IL-6 or PCT levels. Secondly, clini-
cally relevant endpoints should be selected. In the first 
instance, this may well be vasopressor dose under strict 
protocol guidance and adherence. In all cases, inva-
sive hemodynamic monitoring including cardiac out-
put and derived variables must be performed and data 
recorded, in order to have a better understanding on the 
pathophysiological effects of the therapy. With regard to 
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treatment length, this should be guided by response in 
terms of other therapies as well as biomarker reduction 
if possible.
Regarding study endpoints, the consensus panel agreed 
that other endpoints rather than mortality should be cho-
sen in the future to test the actual effect of this therapy. 
Monitoring organ dysfunction with measures like the 
SOFA score may be a better option, in order to under-
stand the physiological effects of CytoSorb treatment. 
Furthermore, a hemodynamic primary endpoint such 
as the change in vasopressor need could also be applied, 
with mortality, ICU length of stay, length of mechanical 
ventilation, dialysis dependence, etc., as secondary end-
points. Finally, potential side effects should be also be 
evaluated like the removal of antibiotics, and especially 
lipophilic antibiotics ones [91].
Conclusions
To date, there is a paucity of data surrounding the use 
of haemoadsorption therapies in the treatment of septic 
shock. Although the consensus statements may appear 
somewhat uncertain, they reflect the current state of our 
understanding. Nevertheless, we hope that the current 
consensus paper also provides a framework for areas that 
need to be addressed in future work rather than contin-
ued reliance on single-centre case series.
For the time being, clinical results with the use of 
cytokine adsorbent therapies are scarce and rather dis-
appointing. More studies should be performed to have 
a precise idea of adsorption properties (kinetics, satura-
bility, potential mediator release, drug removal…) of the 
adsorbent. Plasma cytokine levels before and after treat-
ment of various cytokines should be provided to clearly 
demonstrate the adsorptive properties. Only through 
well-conducted randomized controlled studies with 
appropriate patient selection criteria and endpoints of 
physiological relevance will we know whether haemoad-
sorption techniques are a future therapy for sepsis.
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